Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Investment analysts at HC Wainwright cut their FY2030 earnings per share estimates for Candel Therapeutics in a research note issued on Friday, May 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $2.59 per share for the year, down from their previous estimate of $2.91. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.88) per share.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.16.
Read Our Latest Report on Candel Therapeutics
Candel Therapeutics Stock Performance
Shares of NASDAQ:CADL opened at $7.66 on Monday. Candel Therapeutics has a 12 month low of $4.35 and a 12 month high of $9.27. The business has a 50-day moving average of $6.03 and a two-hundred day moving average of $5.65. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. The firm has a market capitalization of $561.25 million, a PE ratio of -7.82 and a beta of -0.59.
Institutional Trading of Candel Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in CADL. BNP Paribas Financial Markets increased its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after acquiring an additional 4,439 shares during the period. Tower Research Capital LLC TRC boosted its stake in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Candel Therapeutics during the 4th quarter valued at $51,000. ProShare Advisors LLC bought a new position in Candel Therapeutics during the 4th quarter valued at $59,000. Finally, Invesco Ltd. bought a new stake in shares of Candel Therapeutics during the 1st quarter worth $59,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Candel Therapeutics
In related news, Director Paul B. Manning purchased 550,458 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were acquired at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the transaction, the director owned 2,763,527 shares of the company’s stock, valued at $15,061,222.15. This trade represents a 24.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 14.30% of the company’s stock.
Candel Therapeutics Company Profile
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
